Endoscopic Treatment of Vesicoureteral Reflux with Dextranomer/Hyaluronic Acid in Children
نویسندگان
چکیده
PURPOSE The goal of this review is to present current indications, injectable agents, techniques, success rates, complications, and potential future applications of endoscopic treatment for vesicoureteral reflux (VUR) in children. MATERIALS AND METHODS The endoscopic method currently achieving one of the highest success rates is the double hydrodistention-implantation technique (HIT). This method employs dextranomer/hyaluronic acid copolymer, which has been used in pediatric urology for over 10 years and may be at present the first choice injectable agent due to its safety and efficacy. RESULTS While most contemporary series report cure rates of greater than 85% for primary VUR, success rates of complicated cases of VUR may be, depending on the case, significantly lower. Endoscopic treatment offers major advantages to patients while avoiding potentially complicated open surgery. As the HIT method continues to be applied to complex cases of VUR and more outcome data become available, the indication for endoscopic treatment may exceed the scope of primary VUR. CONCLUSIONS Endoscopic injection is emerging as the treatment of choice for VUR in children.
منابع مشابه
Treatment of pediatric vesicoureteral reflux using endoscopic injection of hyaluronic acid/dextranomer gel: intermediate-term experience by a single surgeon.
OBJECTIVES Endoscopic injection of non-animal-stabilized hyaluronic acid/dextranomer gel is an increasingly recognized treatment option for vesicoureteral reflux. The procedure is minor compared with open surgery and, when successful, avoids the need for long-term antibiotic prophylaxis. We present data from 3 years of using non-animal-stabilized hyaluronic acid/dextranomer gel to treat childre...
متن کاملEndoscopic treatment of vesicoureteral reflux with dextranomer/ hyaluronic acid-our experience
Objectives: We report our experience with subureteral submucosal injection therapy for vesicoureteral reflux and determine the safety and efficacy in patients treated with dextranomer/ hyaluronic acid co-polymer. Background: Vesicoureteral reflux affects 1% of children and increases the chances of urinary tract infection, pyelonephritis, hypertension and chronic renal insufficiency. The aim of ...
متن کاملRisk factors for urinary tract infection after dextranomer/hyaluronic acid endoscopic injection.
PURPOSE Endoscopic injection of dextranomer/hyaluronic acid is an option for primary vesicoureteral reflux. Few groups have assessed the rate of urinary tract infection after dextranomer/hyaluronic acid injection. We reviewed our experience with dextranomer/hyaluronic acid injection, and determined the incidence of and risk factors for postoperative urinary tract infection. MATERIALS AND METH...
متن کاملThe treatment of vesicoureteral reflux in children by endoscopic sub-mucosal intra-ureteral injection of dextranomer/hyaluronic acid: A case-series, multi-centre study
BACKGROUND Vesicoureteral reflux is a risk factor for progressive renal damage. In addition to long-term antibiotic prophylaxis and open surgical re-implantation, endoscopic sub-mucosal intra-ureteral injection of implant material is a therapeutic alternative that gained a world-wide preference. OBJECTIVE The aim of this study was to determine the effectiveness and safety of the implant mater...
متن کاملEndoscopic Treatment of Vesicoureteral Reflux
Primary vesicoureteral reflux (VUR) is the most common urological anomaly in children and has been reported in 30 to 50% of those who present with urinary tract infection (UTI). The association of VUR, UTI and renal parenchymal damage is well known. Reflux nephropathy is the cause of endstage renal failure in 3–25% of children and 10–15% of adults. There has been no consensus regarding when med...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Advances in Urology
دوره 2008 شماره
صفحات -
تاریخ انتشار 2008